natgillin/translations-raw huggingface dataset:
Formålene med dette overvågningsprogram er at monitorere de indkomne data om virkning og sikkerhed i behandlingen af medfødte fejl i den primære galdesyresyntese på grund af 3β-hydroxy-Δ5-C27-steroid-oxidoreduktasemangel eller Δ4-3-oxosteroid-5β-reduktasemangel hos spædbørn, børn, unge og voksne. 
The objectives of this surveillance programme is to monitor accumulating data on efficacy and safety in the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency with Orphacol in infants, children, adolescents and adults.
Patienter med nydiagnosticeret hypertriglyceridæmi eller med familiær hypertriglyceridæmi forventes at absorbere cholsyre dårligt i tarmen. 
Patients with newly diagnosed or a family history of familial hypertriglyceridemia are expected to poorly absorb cholic acid in the intestine.
Patienter med nydiagnosticeret hypertriglyceridæmi eller med familiær hypertriglyceridæmi kan have dårlig absorption af cholsyre fra tarmen. 
Patients with newly diagnosed or a family history of familial hypertriglyceridaemia may have poor absorption of cholic acid from the intestine.
Der er i alt rapporteret om resultater af behandling med cholsyre for omkring 60 patienter med 3β-hydroxy-Δ5-C27-steroidoxidoreduktasemangel. 
Overall, cholic acid treatment results for about 60 patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency are reported in the literature.
Sådan skal du tage Orphacol 
How to take Orphacol
Orphacol 250 mg: En hård kapsel indeholder 250 mg cholsyre. 
Orphacol 250 mg: Each hard capsule contains 250 mg of cholic acid.
Gelatine (bovin oprindelse) Titaniumdioxid (E171) Indigotin (E132). 
Gelatin (bovine origin), Titanium dioxide (E171), Carmine blue (E132).
EU/1/13/870/004 [30 hårde kapsler] EU/1/13/870/005 [60 hårde kapsler] EU/1/13/870/006 [120 hårde kapsler] 
EU/1/13/870/004 [30 hard capsules] EU/1/13/870/005 [60 hard capsules] EU/1/13/870/006 [120 hard capsules]
Den kliniske erfaring rapporteret i litteraturen, er fra en patientpopulation med medfødt mangel på 3βhydroxy-Δ5-C27-steroid-oxidoreduktasemangel eller Δ4-3-oxosteroid-5β-reduktasemangel, som primært omfatter spædbørn fra 1 måned samt børn og unge. 
The clinical experience reported in the literature is from a patient population with inborn deficiency of 3β-Hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-Oxosteroid-5β-reductase that includes principally infants from the age of one month, children and adolescents.
Orphacol er indiceret til behandling af medfødte fejl i den primære galdesyresyntese på grund af 3β hydroxy-Δ5-C27-steroid-oxidoreduktasemangel eller Δ4-3-oxosteroid-5β-reduktasemangel hos spædbørn, børn og unge fra 1 måned til 18 år og voksne. 
Orphacol is indicated for the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged 1 month to 18 years and adults.
EU/1/13/870/001 [30 hårde kapsler] EU/1/13/870/002 [60 hårde kapsler] EU/1/13/870/003 [120 hårde kapsler] 
EU/1/13/870/001 [30 hard capsules] EU/1/13/870/002 [60 hard capsules] EU/1/13/870/003 [120 hard capsules]
Orphacol 50 mg: En hård kapsel indeholder 50 mg cholsyre. 
Orphacol 50 mg: Each hard capsule contains 50 mg of cholic acid.
cholsyrer) eller ved Δ4-3-oxosteroid-5β-reduktasemangel (3-oxo-7α-hydroxy- og 3-oxo-7α, 12αdihydroxy-4-cholsyrer) bør bestemmes. 
3β, 7α, 12α-trihydroxy-5-cholenoic acids) or in Δ4-3-Oxosteroid-5β-reductase deficiency (3-oxo-7α-hydroxy- and 3-oxo-7α, 12α-dihydroxy-4-cholenoic acids) should be determined.
Der er begrænsede data for patienter med let til svært nedsat leverfunktion, som er relateret til 3β hydroxy-Δ5-C27-steroidoxidoreduktasemangel eller Δ4-3-oxosteroid-5β-reduktasemangel. 
Limited data are available for patients with minor to severe hepatic impairment related to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency.
Brug af phenobarbial til patienter med 3β-hydroxyΔ5-C27-steroidoxidoreduktasemangel eller Δ4-3-oxosteroid-5β-reduktasemangel, som er i behandling med cholsyre, er kontraindiceret (se pkt. 
Use of phenobarbital in patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency treated with cholic acid is contraindicated (see section 4.3).
Kontakt lægen, før du tager Orphacol, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Orphacol.
INDLÆGSSEDDEL: INFORMATION TIL BRUGEREN Orphacol 50 mg hårde kapsler Orphacol 250 mg hårde kapsler cholsyre Dette lægemiddel er underlagt supplerende overvågning. 
PACKAGE LEAFLET: INFORMATION FOR THE USER Orphacol 50 mg hard capsules Orphacol 250 mg hard capsules
Der er ingen erfaringer med patienter med let nedsat leverfunktion, som skyldes andre årsager end 3β hydroxy-Δ5-C27-steroidoxidoreduktasemangel eller Δ4-3-oxosteroid-5β-reduktasemangel, og der kan ikke gives nogen dosisanbefaling. 
No experience exists in patients with hepatic impairment from causes other than 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency and no dose recommendation can be given.
Gelatine (bovin oprindelse) Titaniumdioxid (E171) Indigotin (E132) Gul jernoxid (E 172). 
Gelatin (bovine origin), Titanium dioxide (E171), Carmine blue (E132), Yellow Iron Oxide (E172).
Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. 
Medicines should not be disposed of via wasterwater or household waste.
- hvis du er allergisk over for cholsyre eller et af de øvrige indholdsstoffer i Orphacol angivet i afsnit 6). 
- if you are allergic to cholic acid or any of the other ingredients of this medicine (listed in section - if you are taking phenobarbital, a medicine to treat epilepsy.
Orphacol 50 mg hårde kapsler 
Orphacol 50 mg hard capsules
Der er i litteraturen rapporteret om resultater af behandling med cholsyre i op til 14 år for syv patienter med Δ4-3-oxosteroid-5β-reduktasemangel. 
Cholic acid treatment results for seven patients with Δ4-3-Oxosteroid-5β-reductase deficiency for up to 14 years are reported in the literature.
Orphacol 250 mg hårde kapsler 
Orphacol 250 mg hard capsules
Galdesten 
Posology
En hård kapsel indeholder 250 mg cholsyre. 
Each hard capsule contains 250 mg cholic acid.
En hård kapsel indeholder 50 mg cholsyre. 
Each hard capsule contains 50 mg cholic acid.
Kapslens indhold: Lactosemonohydrat (se punkt 2 under 'Orphacol indeholder lactose' for yderligere oplysninger), kolloid vandfri silica, magnesiumstearat Kapselskal: Orphacol 50 mg: gelatine, titaniumdioxid (E171), Indigotin (E132); Orphacol 250 mg: gelatine, titaniumdioxid (E171), Indigotin (E132), gul jernoxid (E172). 
Orphacol 250 mg: gelatin, titanium dioxide (E171), carmine blue (E132), yellow iron oxide (E172).
3β-hydroxy-Δ5-C27-steroidoxidoreduktasemangel (3β, 7α-dihydroxy- og 3β, 7α, 12α-trihydroxy-5 
The concentrations of the abnormal bile acid metabolites synthesised in 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency (3β, 7α-dihydroxy- and
Orphacol 50 mg kapsler cholsyre 
Orphacol 50 mg capsules Cholic acid
Det skal du vide, før du begynder at tage Orphacol Sådan skal du tage Orphacol Bivirkninger 
What Orphacol is and what it is used for What you need to know before you take Orphacol How to take Orphacol
Orphacol 250 mg kapsler cholsyre 
Orphacol 250 mg capsules Cholic acid
Orphacol 250 mg hårde kapsler cholsyre 
Orphacol 250 mg hard capsules Cholic acid
Det betyder, at det ikke har været muligt at opnå fuldstændig dokumentation for Orphacol, fordi det drejer sig om en sjælden sygdom, og af etiske grunde. 
This means that due to the rarity of the disease and for ethical reasons it has not been possible to obtain complete information on this medicinal product.
Orphacol 50 mg hårde kapsler cholsyre 
Orphacol 50 mg hard capsules Cholic acid
- Lægen har ordineret Orphacol til dig personligt. 
- This medicine has been prescribed for you.
Dette sammendrag blev sidst ajourført i januar 2013. 
This summary was last updated in January-2013.
Vaccinen gives i halsen i området bag ørerne. 
The vaccine is given in the neck in the area behind the ear.
Hvis du ønsker yderligere oplysninger på grundlag af CVMP's anbefalinger, kan du læse den faglige drøftelse (der ligeledes er en del af EPAR). 
If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR).
Hvis en person ved et uheld injiceres med dette produkt, skal vedkommende straks søge lægehjælp. 
If someone is accidentally injected with this product, they should seek immediate medical advice immediately.
En afvejning af fordele og risici fremgår af afsnit 6 af denne EPAR. 
The benefit-risk balance may be found in module 6 of this EPAR.
Rødme og/eller hævelse omkring injektionsstedet kan forekomme indtil 2 uger efter vaccinationen. 
There may be redness and/or a swelling at the injection site, for up to 2 weeks after vaccination.
Enterotoksikose er en reaktion i tarmene på toksiner fra visse bakterier. 
Enterotoxicosis is a reaction in the intestines to toxins produced by some bacteria.
Porcilis Porcoli Diluvac Forte anvendes til at immunisere mod E. coli, der har adhæsinerne (overfladekomponenter) F4ab (K88ab), F4ac (K88ac), F5 (K99) eller F6 (987P). 
Porcilis Porcoli Diluvac Forte is used to immunise against E. coli which have the adhesins (surface components) F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P).
Søer, der ikke tidligere er vaccineret, skal have to injektioner med seks ugers mellemrum. 
Female pigs that have not been vaccinated should be given two injections with an interval of six weeks between them.
Når soen får injektionen, vil den lille påvirkning bevirke, at soens immunsystem genkender og angriber E. coli bakterierne. 
When the sow is injected, this small exposure helps the pig's immune system to recognise and attack the E. coli bacteria.
Soen bør fortrinsvis vaccineres i anden halvdel af drægtighedsperioden, men ikke senere end to uger før den forventede faringsdato. 
It is preferable to vaccinate female pigs during the second half of their pregnancy, but not within two weeks before the expected date of farrowing.
Vaccinerne (eller dele heraf) var genstand for flere undersøgelser hos drægtige søer af forskellige racer. 
The vaccine (or parts of the vaccine) has been studied in several trials in pregnant pigs of various breeds.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Porcilis Porcoli Diluvac Forte til Intervet International B.V. 
The European Commission granted a marketing authorisation valid throughout the European Union for Porcilis Porcoli Diluvac Forte to Intervet International B.V. on 2 May 2002.
Hovedmålet for behandlingens virkning var den samlede dødelighed hos smågrisene. 
The main measure of effectiveness was the percentage cumulative mortality (overall death rate) of the piglets.
Porcilis Porcoli Diluvac Forte kan fremkalde lette, forbigående kliniske reaktioner (feber, døsighed, nedsat ædelyst) i de første 24 timer efter vaccinationen. 
Porcilis Porcoli Diluvac Forte can cause mild, temporary clinical reactions (fever, lethargy, reduced food intake) during the first 24 hours after vaccination.
Porcilis Porcoli Diluvac Forte indeholder adhæsiner svarende til dem, der findes på overfladen af E. coli bakterier. 
Porcilis Porcoli Diluvac Forte contains adhesins that are found on the surface of E. coli bacteria.
Udvalget for Veterinærlægemidler (CVMP) fandt, at fordelene ved Porcilis Porcoli Diluvac Forte, i form af reduktion af dødelighed og kliniske tegn på enterotoksikose forårsaget af E. coli bakterier, opvejer eventuelle risici. 
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Porcilis Porcoli Diluvac Forte, to reduce death and clinical signs of enterotoxicosis caused by E. coli bacteria, are greater than any risks.
Før hver efterfølgende faring gives en enkelt injektion til opretholdelse af immuniteten. 
To maintain the immunity, a single injection should be given before each subsequent farrowing (giving birth to the piglets).
Porcilis Porcoli Diluvac Forte er vacciner til brug hos grise. 
Porcilis Porcoli Diluvac Forte is a vaccine for use in pigs.
Porcilis Porcoli Diluvac Forte er en injektionsvæske (suspension) og indeholder de aktive stoffer F4ab, F4ac, F5, F6 og LT toksoid . 
It is a suspension for injection and contains the active substances F4ab, F4ac, F5, F6, and LT toxoid.
Derefter blev afkommet både af de vaccinerede søer og af uvaccinerede søer (kontroller) udsat for E. coli, som indeholdt adhæsiner eller LT toksin svarende til vaccinens. 
These pigs were given two injections of the vaccine and then the litters of these pigs, as well as litters where the mother had not been vaccinated (controls), were exposed to E. coli containing the adhesins or LT toxin present in the vaccine.
Andre oplysninger om Porcilis Porcoli Diluvac Forte: 
Other information about Porcilis Porcoli Diluvac Forte:
Porcilis Porcoli Diluvac Forte anvendes til reduktion af dødelighed og kliniske tegn ved enterotoksikose forårsaget af E. coli bakterier hos smågrise i de første dage efter faringen. 
Porcilis Porcoli Diluvac Forte is used to reduce death and clinical signs of enterotoxicosis caused by E. coli bacteria in piglets during the first days of their life.
I alle undersøgelserne mindskede Porcilis Porcoli Diluvac Forte dødeligheden i forhold til kontrolgruppen af smågrise. 
Porcilis Porcoli Diluvac Forte reduced the death rate in all the studies when compared with the control piglets.
Porcilis Porcoli Diluvac Forte gives i en dosis på 2 ml ved intramuskulær injektion i soen. 
Porcilis Porcoli Diluvac Forte is given as a dose of 2 ml by intramuscular (into a muscle) injection to female pigs.
Hvorfor er Porcilis Porcoli Diluvac Forte blevet godkendt? 
Why has Porcilis Porcoli Diluvac Forte been approved?
Hvordan er virkningen af Porcilis Porcoli Diluvac Forte blevet undersøgt? 
How has the effectiveness of Porcilis Porcoli Diluvac Forte been studied?
Hvad er Porcilis Porcoli Diluvac Forte? 
What is Porcilis Porcoli Diluvac Forte?
Udvalget anbefalede udstedelse af markedsføringstilladelse for Porcilis Porcoli Diluvac Forte. 
They recommended that Porcilis Porcoli Diluvac Forte should be given a marketing authorisation.
Hvilke bivirkninger er der ved Porcilis Porcoli Diluvac Forte? 
What are the side effects of Porcilis Porcoli Diluvac Forte?
Hvordan virker Porcilis Porcoli Diluvac Forte? 
How does Porcilis Porcoli Diluvac Forte work?
Hvad anvendes Porcilis Porcoli Diluvac Forte til? 
What is Porcilis Porcoli Diluvac Forte used for?
Hvilken fordel viser undersøgelserne, at der er ved Porcilis Porcoli Diluvac Forte? 
What benefit has Porcilis Porcoli Diluvac Forte shown during the studies?
Fortæl dit apotek det, hvis du bemærker ændringer i tabletternes udseende. 
Tell your pharmacist if you notice any change in the appearance of the tablets.
220 Hafnarfjördur 
220 Hafnarfjörður
Balkanpharma-Dupnitsa AD 3 Samokovsko Shosse Str. 2600 Dupnitsa Bulgarien 
Balkanpharma-Dupnitsa AD 3 Samokovsko Shosse Str. 2600 Dupnitsa Bulgaria
OPA/Aluminium/PVC-Aluminium blisterpakninger. 
OPA/Aluminium/PVC-Aluminium blisters.
Hold flasken tæt tillukket for at beskytte mod lys. 
Keep the bottle tightly closed in order to protect from light.
I tilfælde af overdosering, skal standardbehandling for at fjerne uabsorberet aktiv substans overvejes. 
In the event of overdose, consider standard measures to remove unabsorbed active substance.
Enzymet, der er ansvarlig for metaboliseringen af desloratadin, er ikke blevet identificeret endnu, og nogle interaktioner med andre lægemidler kan derfor ikke fuldstændigt udelukkes. 
The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded.
● ændringer i måden hjertet slår 
• changes in the way the heart beats
Brug af Desloratadine Actavis sammen med mad,drikke og alkohol Desloratadine Actavis kan tages med eller uden mad. 
Desloratadine Actavis with food, drink and alcohol Desloratadine Actavis may be taken with or without a meal.
Dato for første markedsføringstilladelse: 13.01.2012 Dato for seneste fornyelse: 11.11.2016 
Date of latest renewal: 11.11.2016
Med hensyn til varigheden af behandlingen, vil din læge bestemme hvilken type allergisk snue, du lider af, og vil fastsætte, hvor længe du skal tage Desloratadine Actavis. 
Regarding the duration of treatment, your doctor will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Desloratadine Actavis.
SÆRLIGE OPBEVARINGSBETINGELSER Hold flasken tæt tillukket for at beskytte mod lys 
SPECIAL STORAGE CONDITIONS Keep the bottle tightly closed in order to protect from light.
En forbedring af kløe på mere end 50 % blev set hos 55 % af patienterne behandlet med desloratadin sammenlignet med 19 % af patienter behandlet med placebo. 
An improvement in pruritus of more than 50% was observed in 55% of patients treated with desloratadine compared with 19% of patients treated with placebo.
De hyppigste bivirkninger, rapporteret oftere end ved placebo var træthed (1,2 %), mundtørhed (0,8 %) og hovedpine (0,6 %). 
The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2%), dry mouth (0.8%) and headache (0.6%).
Pakningsstørrelser: 7, 10, 14, 20, 21, 30, 50, 90 og 100 tabletter. 
Pack sizes: 7, 10, 14, 20, 21, 30, 50, 90 and 100 tablets.
Reykjavikurvegi 76-78 220 Hafnarfjördur Island 
Reykjavíkurvegi 76-78 220 Hafnarfjörður Iceland
● unormal adfærd 
• abnormal behaviour
Polyethylen flaske indeholdende et tørremiddel og lukket med en polyethylen-hætte. 
Polyethylene bottles containing a desiccant and closed with a polyethylene cap.
Disse omfatter hæmning af frigørelsen af pro-inflammatoriske cytokiner såsom IL-4, IL-6, IL-8 og IL-13 fra humane mastceller/basofile, og ligeledes hæmning af ekspressionen af adhæsionsmolekylet P-selectin på endothelceller. 
These include inhibiting the release of pro-inflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells.
Ved den anbefalede dosering forventes dette lægemiddelikke at påvirke din evne til at køre bil eller anvende maskiner. 
At the recommended dose, this medicine is not expected to affect your ability to drive or use machines.
Desloratadin har vist anti-allergiske egenskaber i in vitro studier. 
Desloratadine has demonstrated anti-allergic properties from in vitro studies.
Der er begrænset erfaring med klinisk effekt ved brug af desloratadin til unge mellem 12 og 17 år (se afsnit 4.8 og 5.1). 
There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).
Frekvenserne er defineret således: Meget almindelig (≥ 1/10), Almindelig (≥ 1/100 til < 1/10), Ikke almindelig (≥ 1/1.000 til < 1/100), Sjælden (≥ 1/10.000 til < 1/1.000), Meget sjælden (< 1/10.000) og Ikke kendt 
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000
Malta eller 
Malta or
Voksne og unge (i alderen 12 år og derover): Den anbefalede dosis Desloratadine Actavis er en tablet en gang daglig. 
Adults and adolescents (12 years of age and over) The recommended dose of Desloratadine Actavis is one tablet once a day.
Sikkerhed og virkning af Desloratadine Actavis 5 mg filmovertrukne tabletter hos børn under 12 år er ikke klarlagt. 
The safety and efficacy of Desloratadine Actavis 5 mg film-coated tablets in children below the age of 12 years have not been established.
Manglende karcinogent potentiale blev vist i undersøgelser med desloratadin og loratadin. 
The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.
Effekten af desloratadin-tabletter er ikke blevet tydeligt vist i studier med unge patienter mellem 12 og 17 år. 
The efficacy of desloratadine tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.
Desloratadine Actavis er et lægemiddel mod allergi, som ikke gør dig døsig. 
Desloratadine Actavis is an antiallergy medicine that does not make you drowsy.
Hvis du har glemt at tage Desloratadine Actavis Hvis du glemmer at tage din medicin til tiden, så tag den snarest muligt og vend så tilbage til din sædvanlige medicineringsplan. 
If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule.
Tabletovertræk: Hypromellose 6cP, titandioxid (E171), macrogol 6000, indigocarmin aluminium lak (E132). 
Tablet coating: Hypromellose 6cP, titanium dioxide (E171), macrogol 6000, indigo carmine aluminum lake (E132).
Yderligere information om dette lægemiddel er tilgængelig på Det europæiske Lægemiddelagenturs (EMEAs) hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
• krampeanfald • unormale prøver for leverfunktion 
• liver inflammation • abnormal liver function tests
I et separat studie havde grapefrugtjuice ingen indflydelse på omsætningen af desloratadin. 
In another study, grapefruit juice had no effect on the disposition of desloratadine.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/11/745/010 30 filmovertrukket tablet EU/1/11/745/011 100 filmovertrukne tabletter 
MARKETING AUTHORISATION NUMBER(S) EU/1/11/745/010 30 film-coated tablets EU/1/11/745/011 100 film-coated tablets
Brug ikke lægemiddlet efter den udløbsdato, der står på æsken, flaskeetiket og blister efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton, bottle label and blister after ‘EXP'.
Pakningsstørrelser: 30 og 100 tabletter 
Pack sizes: 30 and 100 tablets.
Blå, runde med en diameter på 6 mm, bikonvekse, filmovertrukne tabletter mærket med ”LT” på den ene side. 
Blue coloured, round, with diameter of 6 mm, biconvex, film-coated tablets with the marking ‘LT' engraved on one side.
7 filmovertrukket tablet 10 filmovertrukne tabletter 14 filmovertrukne tabletter 20 filmovertrukne tabletter 21 filmovertrukne tabletter 30 filmovertrukne tabletter 50 filmovertrukne tabletter 90 filmovertrukne tabletter 100 filmovertrukne tabletter 
7 film-coated tablets 10 film-coated tablets 14 film-coated tablets 20 film-coated tablets 21 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets
Du skal udvise forsigtighed, hvis du tager Desloratadine Actavis sammen med alkohol. 
Use caution when taking Desloratadine Actavis with alcohol.
Desloratadine Actavis 5 mg filmovertrukne tabletter pakkes i: Blisterpakninger: 7, 10, 14, 20, 21, 30, 50, 90 eller 100 tabletter. 
Desloratadine Actavis 5 mg film-coated tablets are packed in: Blister packs: 7, 10, 14, 20, 21, 30, 50, 90 or 100 tablets.
I tilfælde af svær nyreinsufficiens bør desloratadin anvendes med forsigtighed (se pkt. 
In the case of severe renal insufficiency, desloratadine should be used with caution (see section 5.2).
I et farmakokinetisk studie, i hvilket patientdemografika var sammenlignelige med dem for den almindeligt forekommende sæsonbetinget allergisk rhinitis population, opnåede 4 % af forsøgspersonerne en højere koncentration af desloratadin. 
In a pharmacokinetic trial in which patient demographics were comparable to those of the general seasonal allergic rhinitis population, 4% of the subjects achieved a higher concentration of desloratadine.
Desloratadin var effektivt til at lindre generne ved sæsonbetinget allergisk rhinitis, vist ved den total score i rhino-konjunktivitis livskvalitetsspørgeskemaet. 
Desloratadine was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.